

Overview
When your patient is hospitalised for COVID-19 but also has chronic kidney disease (CKD), how do you strike a balance between the risk of acute kidney injury and the benefits of remdesivir treatment?
How do you structure treatment plans in patients with multiple comorbidities while avoiding the potential hazards caused by adverse drug–drug interactions?
How do you manage COVID-19 infection and its rebound in immunocompromised patients, in the light of sparse research data?
Upon completion of this module, the participant will be able to: